Table 2.

Pooled incidence of common treatment-related adverse events (pooled rate ≥5%) in patients receiving pembrolizumab-based regimens.

System/adverse event	No. of studies (k)	Events/total	Pooled rate (%)	95% CI	I² (%)	p (Q test)
Hematologic
Neutrophil count decreased	3	454/1730	24.9	10.3–49.0	98.5	<0.001
Anemia	3	447/1730	24.7	19.0–31.4	90.1	<0.001
Neutropenia	2	230/1289	17.8	15.8–20.0	0	0.774
Decreased platelet count	3	338/1730	15.7	5.2–38.9	97.4	<0.001
WBC decreased	3	235/1730	12.7	5.9–25.2	96.2	<0.001
Thrombocytopenia	2	110/1289	7.7	3.9–14.6	90.3	0.001
Gastrointestinal
Nausea	3	650/1730	36.9	30.6–43.6	87.2	<0.001
Diarrhea	3	500/1730	27.6	15.8–43.7	96.8	<0.001
Decreased appetite	3	392/1730	22.9	17.4–29.6	88.1	<0.001
Vomiting	3	369/1730	19.7	13.5–27.9	93.8	<0.001
Stomatitis	2	99/945	10.2	4.8–20.2	92.7	<0.001
Mucosal inflammation	2	94/945	10	7.4–13.4	58.3	0.121
Constipation	2	68/945	7.1	4.1–12.1	81.3	0.021
Dysgeusia	2	49/945	5.2	4.0–6.8	0	0.531
Skin
PPE syndrome	3	343/1730	18.6	11.9–27.8	93.2	<0.001
Rash	2	87/945	9.2	7.5–11.3	0	0.444
Pruritus	2	80/945	8.5	6.8–10.7	16	0.275
Constitutional
Fatigue	3	375/1730	21.8	19.6–24.1	17.2	0.299
Asthenia	3	178/1730	9.9	6.8–14.1	81	0.005
Weight decreased	2	95/945	9.1	2.8–26.1	96.4	<0.001
Hepatic
AST increased	2	220/1226	17.9	15.9–20.2	0	0.772
ALT increased	2	171/1226	14.2	11.5–17.3	52.8	0.145
Bilirubin increased	2	113/1226	9.2	7.4–11.3	25.6	0.246
Endocrine
Hypothyroidism	3	273/1730	15.3	7.7–28.2	96.7	<0.001
Neurologic
Peripheral neuropathy	3	245/1730	11.9	5.3–24.6	95.5	<0.001
Peripheral sensory neuropathy	3	224/1730	11.4	6.5–19.5	93.5	<0.001